Debut Biotech, a San Diego, CA-based developer of a biomanufacturing platform harnessing cell-free enzymes, raised $22.6M in Series A financing.
The round was led by Material Impact with participation from Cultivian Sandbox Ventures, Fine Structure Ventures, ACVC Ventures, Humboldt Fund, Cantos Ventures, as well as existing investors including KdT Ventures.
The company will use the funds to commercialize ingredients developed from its proprietary cell-free biomanufacturing platform.
Led by CEO Joshua Britton, Debut Biotech has developed a biomanufacturing platform which utilizes cell-free approaches to produce rare, high-value and novel compounds and improve traditional ingredient manufacturing. It has applications across various industries from food and wellness products to cosmetics, colors, therapeutics and other industrial applications. In order to scale the commercialization of its technology and expand into new products, Debut Biotech will expand its footprint to a 26,000 square foot facility in San Diego and triple the size of its team across locations in San Diego and Atlanta. These facility investments will enable manufacturing to be done entirely in the United States.
FinSMEs
12/08/2021